Literature DB >> 19171552

Nail toxicity induced by cancer chemotherapy.

Peter Gilbar1, Alice Hain, Veta-Marie Peereboom.   

Abstract

PURPOSE: To provide a comprehensive literature review of chemotherapy-induced nail toxicity, including clinical presentation, implicated drugs and approaches for prevention and management. DATA SOURCE: A search of MEDLINE and EMBASE (1966-2008) databases was conducted using the terms (and variations of the terms) antineoplastic agents, nails, nail toxicity, onycholysis, and paronychia. Bibliographies from selected articles were reviewed for appropriate references. DATA EXTRACTION: The retrieved literature was reviewed to include all articles relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of chemotherapy-induced nail toxicity. DATA SYNTHESIS: Nail toxicity is a relatively uncommon adverse effect linked to a number of chemotherapeutic agents. Clinical presentation varies, depending on which nail structure is affected and the severity of the insult. Nail changes may involve all or some nails. Toxicity may be asymptomatic and limited to cosmetic concerns, however, more severe effects, involving pain and discomfort can occur. Taxanes and anthracyclines are the antineoplastic drug groups most commonly implicated. It is suggested that the administration schedule may influence the incidence of nail abnormalities, for example reported cases linked to the weekly administration of paclitaxel.Before instituting chemotherapy, patients should be educated regarding potential nail toxicities and strategies for prevention implemented. Management includes appropriate nail cutting, avoiding potential irritants, topical, or oral antimicrobials, and possibly cessation or dose reduction of the offending agent. Cryotherapy, through the application of frozen gloves or socks, has been beneficial in reducing docetaxel-induced nail toxicity and may be effective for other drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171552     DOI: 10.1177/1078155208100450

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  16 in total

Review 1.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

2.  Cyclophosphamide and Doxorubicin Induced Melanonychia: A Case Report.

Authors:  Vivek Bhanubhai Prajapati; Sharath Madhyastha; Raviraj Acharya; Vinaya Gopalaswamy; Akhila Doddamani
Journal:  J Clin Diagn Res       Date:  2017-01-01

3.  Nail Pyogenic Granuloma following Treatment with Blinatumomab.

Authors:  Dilshad Paurobally; Josette Andre; Bertrand Richert
Journal:  Skin Appendage Disord       Date:  2017-08-31

4.  A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.

Authors:  Kara D Capriotti; Milan Anadkat; Jennifer Choi; Benjamin Kaffenberger; Beth McLellan; Samuel Barone; Oluwaseun Kukoyi; Shari Goldfarb; Mario Lacouture
Journal:  Invest New Drugs       Date:  2019-06-26       Impact factor: 3.850

5.  A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer.

Authors:  Audrey Morrison; Rebecca Marshall-McKenna; Angus K McFadyen; Cathy Hutchison; Ann-Marie Rice; Lynne Stirling; Pauline McIlroy; Iain R Macpherson
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

6.  Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen.

Authors:  Santosh Kumar; Rakesh Dixit; Saurabh Karmakar; Sayan Paul
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

7.  Conservation of tubulin-binding sequences in TRPV1 throughout evolution.

Authors:  Puspendu Sardar; Abhishek Kumar; Anita Bhandari; Chandan Goswami
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

8.  Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy.

Authors:  Kayoko Kibata; Takeshi Tamaki; Noriko Inagaki; Makoto Ogata; Toshiki Shimizu; Shosaku Nomura
Journal:  Oncol Lett       Date:  2013-02-05       Impact factor: 2.967

9.  Chromonychia secondary to chemotherapy.

Authors:  Marien Lopes; Clarice Jordão; Rachel Grynszpan; Celso Sodré; Marcia Ramos-E-Silva
Journal:  Case Rep Dermatol       Date:  2013-06-06

10.  Effect of YH0618 soup on chemotherapy-induced toxicity in patients with cancer who have completed chemotherapy: study protocol for a randomized controlled trial.

Authors:  Jie-Shu You; Jian-Ping Chen; Jessie S M Chan; Ho-Fun Lee; Mei-Kuen Wong; Wing-Fai Yeung; Li-Xing Lao
Journal:  Trials       Date:  2016-07-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.